Alterity Therapeutics: Nearing Phase 3 Kickoff, Stock Set to Rise
AI Prediction of Alterity Therapeutics Limited (ATHE)
Alterity Therapeutics, a clinical-stage biotech company, is poised for significant advancements with its lead asset ATH434 targeting Multiple System Atrophy (MSA). Positive Phase 2 results and ongoing regulatory discussions are key catalysts.
Alterity Therapeutics is focused on developing ATH434, a promising treatment for Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The company has reported positive Phase 2 results and is advancing towards a pivotal Phase 3 trial. With ATH434 not yet approved and further FDA alignment needed, the stock's movement is likely tied to clinical and regulatory advancements. The upcoming End-of-Phase-2 meeting and potential initiation of Phase 3 trials serve as critical near-term catalysts that could significantly impact the company's valuation and stock price.
ATHE Report Information
Prediction Date2026-03-30
Close @ Prediction$3.16
Mkt Cap96m
IPO DateN/a
AI-derived Information
Recent News for ATHE
- Jul 7, 7:05 am — Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy (GlobeNewswire RSS)
- Jun 17, 6:05 am — ATHE files foreign issuer report with market-relevant terms (ScanScor Filing Bot)
- Jun 16, 6:04 am — ATHE files foreign issuer report with market-relevant terms (ScanScor Filing Bot)
- Jun 15, 6:01 am — ATHE files foreign issuer report with market-relevant terms (ScanScor Filing Bot)
- Jun 12, 6:07 am — ATHE files foreign issuer report with market-relevant terms (ScanScor Filing Bot)
- Jun 9, 7:05 am — Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy (GlobeNewswire RSS)
- Jun 9, 6:00 am — ScanScor Filing Bot: ATHE files foreign issuer report with market-relevant terms (ScanScor Filing Bot)
- Jun 4, 8:50 am — ScanScor Filing Bot: ATHE files foreign issuer report with market-relevant terms (ScanScor Filing Bot)
- May 19, 7:25 am — Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy (GlobeNewswire RSS)
- May 11, 7:25 am — Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy (GlobeNewswire RSS)
- May 7, 7:25 am — Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 (GlobeNewswire)
- Apr 30, 7:25 am — Alterity Therapeutics Releases Appendix 4C - Q3 FY26 Quarterly Cash Flow Report & Corporate Update (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest